Views & Analysis | Perspectives on pharma industry issues

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

R&D

Cancer patient in hospital bed speaking with doctor

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

R&D

Test tubes being prepared for flow cytometry

Overcoming 6 data management challenges in flow cytometry

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, making it fundamental to medical research.

Patients

Interview at LSX 2026 with Hans Schambye

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Digital

BIO-Europe Spring podcast with Kashif Sadiq

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

Market Access

Why the NHS needs to maximise the impact of biosimilars

Ensuring the long-term sustainability of the NHS increasingly appears to be an unfathomable prospect.

Sales & Marketing

Sponsored

5 strategies to retain top talent

The pharma sales industry is in the midst of rapid transformation, fuelled by digital disruption and dynamic market forces.

R&D

Delivery: The key to navigating pharmacy deserts in 2025

Pharmacy closures are accelerating fast.

Sales & Marketing

Commercial teams are running yesterday's plays. AI just chan...

What leading companies are building now is fundamentally different: decision systems.

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

Digital

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

Digital

Sponsored

AI and digital innovation & the transformation of care deliv...

It goes without saying that healthcare is in the midst of a digital, AI-accelerated transformation.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

A panel on direct-to-patient at Reuters Pharma USA

In DTC's watershed moment, trust and partnership are key

More and more pharma companies are turning to direct-to-patient access models. But the consensus at Reuters Pharma USA is that they can't do it alone.

Oncology

Interview with Vicky Brown at Pharma USA 2026

Hernexeos and what’s next, with Vicky Brown

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent US approval for Hernexeos in NSCLC.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Patients

LSX2026: On promise and patience, with Hans Schambye

At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.

Patients

World Bipolar Day: Recognising bipolar I disorder and addres...

BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.

Patients

Interview with Phil Johnson at Pharma US 26

Using patient data to fill in GLP-1 blind spots, with Phil J...

At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.

LSX2026: On a therapeutic vision for ocular disease, with Al...

Human behaviour in cancer screening trials: A variable that ...

Overcoming 6 data management challenges in flow cytometry

LSX2026: On promise and patience, with Hans Schambye

Creating what nature has not from AI and computational molec...

Why the NHS needs to maximise the impact of biosimilars

5 strategies to retain top talent

Delivery: The key to navigating pharmacy deserts in 2025

Commercial teams are running yesterday's plays. AI just chan...

What HCPs Say Pharma Gets Wrong About Survey Research

Creating what nature has not from AI and computational molec...

AI and digital innovation & the transformation of care deliv...

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

In DTC's watershed moment, trust and partnership are key

Hernexeos and what’s next, with Vicky Brown

Day One's big bet on tovorafenib just keeps paying off

Collaboration & personalisation in rare disease R&D, with AO...

LSX2026: On promise and patience, with Hans Schambye

World Bipolar Day: Recognising bipolar I disorder and addres...

Using patient data to fill in GLP-1 blind spots, with Phil J...

LSX2026: On a therapeutic vision for ocular disease, with Al...

Human behaviour in cancer screening trials: A variable that ...

Overcoming 6 data management challenges in flow cytometry

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks